Review decision: April 2016
We checked this guideline and decided that it should not be updated at this time. For details, see the update decision, decision matrix, response to stakeholder comments, and the process for deciding if an update is needed.
In August 2016, the footnote to recommendations 1.4.11 and 1.4.12 were amended to cover the new advice from the Medicines and Healthcare products Regulatory Agency (MHRA) about safety concerns related to ivabradine (June 2014 and December 2014) and nicorandil (January 2016).
Next review date: 2017
This guideline offers evidence-based advice on the care and treatment of adults diagnosed with stable angina.
Stable angina is usually caused by coronary heart disease, a condition in which blood vessels in the heart become narrowed by a build up of fat. This reduces the supply of blood and oxygen to the heart. The most common symptom of stable angina is pain or a feeling of discomfort or tightness in the chest, which can often spread to the jaw, back, shoulders and arms.
This guideline was previously called management of stable angina.
Recommendations 1.5.2 and 1.5.12 of this guideline partially update recommendation 1.2 of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.